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A B S T R A C T
Purpose
To endorse the American Urological Association (AUA)/American Society for Radiation Oncology
(ASTRO) guideline on adjuvant and salvage radiotherapy after prostatectomy. The American
Society of Clinical Oncology (ASCO) has a policy and set of procedures for endorsing clinical
practice guidelines developed by other professional organizations.
Methods
The guideline on adjuvant and salvage radiotherapy after prostatectomy was reviewed for
developmental rigor by methodologists. An ASCO endorsement panel then reviewed the content
and recommendations.
Results
The panel determined that the guideline recommendations on adjuvant and salvage radiotherapy
after prostatectomy, published in August 2013, are clear, thorough, and based on the most
relevant scientific evidence. ASCO endorsed the guideline on adjuvant and salvage radiotherapy
after prostatectomy, adding one qualifying statement that not all candidates for adjuvant or salvage
radiotherapy have the same risk of recurrence or disease progression, and thus, risk-benefit ratios
are not the same for all men. Those at the highest risk for recurrence after radical prostatectomy
include men with seminal vesicle invasion, Gleason score 8 to 10, extensive positive margins, and
detectable postoperative prostate-specific antigen (PSA).
Recommendations
Physicians should discuss adjuvant radiotherapy with patients with adverse pathologic findings at
prostatectomy (ie, seminal vesicle invasion, positive surgical margins, extraprostatic extension)
and salvage radiotherapy with patients with PSA or local recurrence after prostatectomy. The
discussion of radiotherapy should include possible short- and long-term adverse effects and
potential benefits. The decision to administer radiotherapy should be made by the patient and
multidisciplinary treatment team, keeping in mind that not all men are at equal risk of recurrence
or clinically meaningful disease progression. Thus, the risk-benefit ratio will differ for each
patient.
J Clin Oncol 32. © 2014 by American Society of Clinical Oncology
INTRODUCTION
In 2014, an estimated 233,000 men in the United
States will be diagnosed with prostate cancer,1 and
an estimated 29,480 will die as a result of it.1 For men
eligible for surgery with curative intent, radical pros-
tatectomy is an option; however, approximately one
third of all patients treated this way will experience
recurrence within a decade.2 Risk for recurrence af-
ter radical prostatectomy is greater for men with any
of the following: positive surgical margins, seminal
vesicle invasion, extraprostatic extension, higher
Gleason score, and detectable postoperative
prostate-specific antigen (PSA).2,3 The purpose of
this American Society of Clinical Oncology (ASCO)
endorsement is to support the American Urological
Association (AUA)/American Society for Radiation
Oncology (ASTRO) guideline on adjuvant and sal-
vage radiotherapy after prostatectomy by Thomp-
son et al,2 published in August 2013 in Journal of
Urology. This ASCO endorsement reinforces the
recommendations offered in the AUA/ASTRO
guideline and acknowledges the effort put forth
by the AUA/ASTRO to produce an evidence-
based guideline informing practitioners who care
for patients being considered for adjuvant and
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THE BOTTOM LINE
ASCO Endorses the Adjuvant and Salvage Radiotherapy After Prostatectomy: AUA/ASTRO Clinical Practice
Guideline, With Qualifying Statements Developed by the Endorsement Panel
Guideline Questions
The four principal questions involved:
1) Patient counseling
2) Use of radiotherapy in the adjuvant and salvage contexts
3) Definition of biochemical recurrence
4) Conduct of a restaging evaluation
Target Population
● Men offered prostate cancer treatment with prostatectomy
Target Audience
● Primary care providers, radiation and medical oncologists, urologists, and other providers
Methods
● An ASCO Endorsement Panel was convened to consider endorsing the Adjuvant and Salvage Radiotherapy After
Prostatectomy: AUA/ASTRO Clinical Practice Guideline recommendations, which were based on a systematic review of
the medical literature. The ASCO Endorsement Panel evaluated the methodology employed in the AUA/ASTRO guideline
using the AGREE II review instrument. The ASCO Endorsement Panel carefully reviewed the AUA/ASTRO guideline
content to determine appropriateness for ASCO endorsement.
ASCO Key Recommendations for Adjuvant and Salvage Radiotherapy After Prostatectomy: ASCO Qualifying
Statements (in bold italics)
1. Patients who are being considered for management of localized prostate cancer with radical prostatectomy should be
informed of the potential for adverse pathologic findings that portend a higher risk of cancer recurrence and that these
findings may suggest a potential benefit of additional therapy after surgery.
2. Patients with adverse pathologic findings, including seminal vesicle invasion, positive surgical margins, and
extraprostatic extension, should be informed that adjuvant radiotherapy, compared with radical prostatectomy only,
reduces the risk of biochemical prostate-specific antigen (PSA) recurrence, local recurrence, and clinical progression of
cancer. They should also be informed that the impact of adjuvant radiotherapy on subsequent metastases and overall
survival is less clear; one of two randomized controlled trials that addressed these outcomes indicated a benefit, but the
other trial did not demonstrate a benefit (reduced risk of metastasis and death).
3. Physicians should offer* adjuvant radiotherapy to patients with adverse pathologic findings at prostatectomy, including
seminal vesicle invasion, positive surgical margins, or extraprostatic extension, because of demonstrated reductions in
biochemical recurrence, local recurrence, and clinical progression.
4. Patients should be informed that the development of a PSA recurrence after surgery is associated with a higher risk of
development of metastatic prostate cancer or death resulting from the disease.† Congruent with this clinical principle,
physicians should regularly monitor PSA after radical prostatectomy to enable early administration of salvage therapies
if appropriate.
5. Clinicians should define biochemical recurrence as a detectable or increasing PSA value after surgery that is  0.2 ng/
mL, with a second confirmatory level  0.2 ng/mL.‡
6. A restaging evaluation§ in a patient with a PSA recurrence may be considered.
(continued on following page)
Freedland et al
2 © 2014 by American Society of Clinical Oncology JOURNAL OF CLINICAL ONCOLOGY
from 132.239.1.230
Information downloaded from jco.ascopubs.org and provided by at UNIV CALIFORNIA SAN DIEGO on November 3, 2014
Copyright © 2014 American Society of Clinical Oncology. All rights reserved.
salvage radiotherapy after prostatectomy. The issues addressed in
the original guideline as well as this endorsement are the use of radio-
therapy in the adjuvant and salvage settings, definition of biochemical
recurrence, conduct of a restaging evaluation, and role of patient
counseling. Although we are, overall, endorsing the recommenda-
tions, we believed it was important to clarify certain aspects of the
guideline as well as add a qualifying statement to help put these
guidelines into clinical context.
THE BOTTOM LINE (CONTINUED)
7. Physicians should offer* salvage radiotherapy to patients with PSA or local recurrence after radical prostatectomy in
whom there is no evidence of distant metastatic disease.
8. Patients should be informed that the effectiveness of radiotherapy for PSA recurrence is greatest when administered at
lower levels of PSA.
9. Patients should be informed of the possible short- and long-term urinary, bowel, and sexual adverse effects of
radiotherapy as well as of the potential benefits of controlling disease recurrence.¶
Qualifying Statements
*The word “offer” should be interpreted as having a detailed discussion with the patient about the risks and benefits of adjuvant
radiotherapy. This discussion should be heavily influenced by our additional qualifying statement¶ and include a thorough
discussion of the absolute risk of recurrence in light of exact pathologic findings and postoperative PSA levels. As such, although
adjuvant ratiotherapy seems to be equally effective for all stages and postoperative PSA levels in terms of reducing the relative
risk of recurrence, the absolute benefit is influenced by the absolute risk of recurrence. For men at low risk of recurrence, the
benefits are modest. Moreover, all potential benefits must be weighed against the known risks.
†This Endorsement Panel concurs, as noted in the discussion for Recommendation 3 and in our qualifying statement,¶ that not
all men are at equal risk of recurrence. However, at this time, there are insufficient data to recommend different follow-up
strategies based on differing risk of recurrence, and thus, all men should be observed after surgery.
‡Defining an exact cut point for PSA recurrence is challenging. We acknowledge this difficulty, and although we agree that 0.2
ng/mL is a reasonable cutoff and is widely used in research publications and in clinical practice, the benefits of using this cut point
versus others are unclear. As such, we believe that the evidence to support this recommendation was clinical practice rather than
clinical evidence.
§Although the endorsement panel agrees with this statement, the discussion centered on which imaging modalities to use. At this
time, there is no clear consensus, and unfortunately, all imaging modalities have limited sensitivity and specificity in the low PSA
range, where salvage radiotherapy is most effective (ie, PSA < 1 ng/mL). We note that this is a rapidly evolving field with much
research being performed, and it is hoped that in the future, there will be more clarity on this point.
Although PSA control rates are best when salvage radiotherapy is administered when the PSA is < 1 ng/mL, there is no guarantee
of cure, because salvage radiotherapy is not curative for all men. There are many technical issues related to measuring the rate
of PSA increase, typically measured as PSA doubling time (PSADT; ie, when to start counting, how many values, over what time
period, and so on), but data suggest a short PSADT predicts a poor response to salvage radiotherapy in terms of PSA control.
However, because these men are at the highest risk of clinically meaningful progression, they stand to gain the most from salvage
radiotherapy, and indeed, retrospective data suggest that salvage radiotherapy improves overall survival, albeit only in those with
a short PSADT.
¶Not all men who are candidates for adjuvant radiotherapy have the same risk of recurrence, and although radiotherapy
is equally effective in terms of relative risk reduction, not all men will derive the same benefit. Items such as Gleason score
(especially Gleason score 8 to 10), pathologic findings (especially seminal vesicle invasion or extensive positive margins), and
an elevated postoperative PSA place men at particularly high risk of recurrence or clinical progression, and these men likely
derive the greatest benefit in terms of absolute risk reduction from adjuvant radiotherapy. For other men, the absolute risk
benefit is likely lower, resulting in a less favorable risk-benefit ratio. Similarly, not all men who develop a PSA recurrence
have the same risk of clinically meaningful disease progression, and therefore, the risk-benefit ratio for salvage radiotherapy
is likewise different for each patient.
Additional Resources
More information, including a Data Supplement, a Methodology Supplement, slide sets, and clinical tools and resources, is available at
www.asco.org/endorsements/adjuvantRTprostatectomy. Patient information is available at www.cancer.net. A link to the Adjuvant
and Salvage Radiotherapy After Prostatectomy: AUA/ASTRO Clinical Practice Guideline can be found at http://www.auanet.org/
education/guidelines/radiation-after-prostatectomy.cfm. ASCO believes that cancer clinical trials are vital to inform medical decisions
and improve cancer care, and that all patients should have the opportunity to participate.
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OVERVIEW OF ASCO GUIDELINE ENDORSEMENT PROCESS
ASCO has policies and procedures for endorsing practice guidelines
that have been developed by other professional organizations. The
goal of guideline endorsement is to increase the number of high-
quality, ASCO-vetted guidelines available to the ASCO membership.
The ASCO endorsement process involves an assessment by ASCO
staff of candidate guidelines for methodologic quality using the Rigour
of Development subscale of the Appraisal of Guidelines for Research
and Evaluation II (AGREE II) instrument (details provided in Meth-
odology Supplement).
Disclaimer
The clinical practice guideline and other guidance published
herein are provided by ASCO to assist providers in clinical decision
making. The information herein should not be relied on as being
complete or accurate, nor should it be considered as inclusive of all
proper treatments or methods of care or as a statement of the standard
of care. With the rapid development of scientific knowledge, new
evidence may emerge between the time information is developed and
when it is published or read. The information is not continually
updated and may not reflect the most recent evidence. The informa-
tion addresses only the topics specifically identified herein and is not
applicable to other interventions, diseases, or stages of diseases. This
information does not mandate any particular course of medical care.
Furthermore, the information is not intended to substitute for the
independent professional judgment of the treating provider, because
the information does not account for individual variation among
patients. For each recommendation, high, moderate, or low confi-
dence that the recommendation reflects the net effect of a given course
of action is indicated. The use of words like must, must not, should,
and should not indicates that a course of action is recommended or
not recommended for either most or many patients, but there is
latitude for the treating physician to select other courses of action in
individual cases. In all cases, the selected course of action should be
considered by the treating provider in the context of treating the
individual patient. Use of the information is voluntary. ASCO pro-
vides this information on an as-is basis and makes no warranty, ex-
press or implied, regarding the information. ASCO specifically
disclaims any warranties of merchantability or fitness for a particular
use or purpose. ASCO assumes no responsibility for any injury or
damage to persons or property arising out of or related to any use of
this information or for any errors or omissions.
Guideline and Conflicts of Interest
The endorsement panel was assembled in accordance with the
ASCO Conflicts of Interest Management Procedures for Clinical Prac-
tice Guidelines (summarized at www.asco.org/rwc). Members of the
endorsement panel completed the ASCO disclosure form, which re-
quires disclosure of financial and other interests that are relevant to the
subject matter of the guideline, including relationships with commer-
cial entities that are reasonably likely to experience direct regulatory or
commercial impact as the result of promulgation of the guideline.
Categories for disclosure include employment relationships, consult-
ing arrangements, stock ownership, honoraria, research funding, and
expert testimony. In accordance with these procedures, the majority of
the members of the endorsement panel did not disclose any such
relationships.
Clinical Questions and Target Population
The AUA/ASTRO guideline addressed four principle questions
regarding (1) patient counseling, (2) use of radiotherapy in the adju-
vant and salvage contexts, (3) definition of biochemical recurrence,
and (4) conduct of a restaging evaluation. The clinical questions and
corresponding recommendations are listed in Table 1.
The target population for the AUA/ASTRO guideline is male
patients with prostate cancer who were previously treated with radical
prostatectomy and are being considered for adjuvant or salvage treat-
ment with radiotherapy.
Summary of Adjuvant and Salvage
Radiotherapy After Prostatectomy Guideline
Development Methodology
The guideline was developed by the prostate guidelines panel of
the AUA/ASTRO and included urologists, radiation oncologists, and a
medical oncologist. The systematic literature review included a search
of the PubMed, EMBASE, and Cochrane Collaboration databases
from January 1, 1990, to December 15, 2012. Articles were eligible for
inclusion if they reported on the use of radiotherapy after prostatec-
tomy (if PSA data were available for at least 75% of all patients),
quality-of-life outcomes, adverse effect outcomes, or imaging strate-
gies to determine appropriateness of radiotherapy when recurrence is
suspected. Preclinical studies, commentaries, editorials, and review
articles were excluded. The searches identified 294 studies eligible for
inclusion in the guideline.
Therecommendations formedweredeemedtobeeither: standards,
recommendations, options, clinical principles, or expert opinions, de-
pendingonthequalityandquantityofsupportingevidence.Oncerecom-
mendations were drafted, the guideline was subjected to a rigorous
external review process, where the document was distributed to 75 peer
reviewers (returned, n  44; response rate, 59%). All submitted com-
ments were reviewed, and the draft was revised as needed. The guideline
was then submitted to the governing body of each organization and then
to the AUA and ASTRO Boards of Directors for final approval.
RESULTS OF THE ASCO METHODOLOGY REVIEW
The methodology review of the AUA/ASTRO guideline was com-
pleted independently by two ASCO guideline staff members using the
Rigour of Development subscale from the AGREE II instrument.
Detailed results of the scoring for this guideline are available on re-
quest to guidelines@asco.org. Overall, the adjuvant and salvage radio-
therapy after prostatectomy guideline itself scored an acceptable 66%.
Although this guideline was well reported overall, no information was
provided regarding plans for future updating, decreasing the score in
the Rigour of Development domain. The preliminary ASCO content
reviewers of the adjuvant and salvage radiotherapy after prostatec-
tomy guideline, as well as the ASCO endorsement panel, found the
recommendations well supported in the original guideline. Each sec-
tion, including introduction, methods, background, and results sec-
tions, was clear and well referenced from the systematic review.
This is the most recent information as of the publication date.
To view updates and the most recent information and to submit
new evidence, please visit www.asco.org/endorsements/adjuvantRT
prostatectomy or the ASCO guidelines wiki at www.asco.org/
guidelineswiki.
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METHODS AND RESULTS OF ASCO UPDATED
LITERATURE REVIEW
ASCO guidelines staff updated the adjuvant and salvage radiotherapy after
prostatectomy guideline literature search, using the same PubMed search
strategy that was used in the original guideline. The search was restricted to
articles published in English and to systematic reviews, meta-analyses, and
randomized controlled trials.
The updated search yielded 319 records. A review of these results by the
methodology team resulted in 16 abstracts being reviewed by the panel co-
chairs, which revealed one recently published article4 that supported a quali-
fying statement.
RESULTS OF ASCO CONTENT REVIEW
The ASCO endorsement panel (members listed in Table 2) reviewed
the adjuvant and salvage radiotherapy after prostatectomy guideline
and concurs that the recommendations are clear, thorough, and based
on the most relevant scientific evidence in this content area and pres-
ent options that will be acceptable to patients. Overall, the ASCO
endorsement panel agrees with the recommendations as stated in the
guideline, with minor clarifications noted, in addition to one qualify-
ing statement.
DISCUSSION
The ASCO endorsement panel wants to highlight and qualify some of
the statements from the adjuvant and salvage radiotherapy after pros-
tatectomy guideline regarding better clarifying the risks and benefits
and more clearly discussing what is meant by the word offer. Although
Recommendations 1 and 9 were accepted as is, qualifying statements
were added for the rest as follows:
Recommendation 2
In the final sentence of the guideline statement, the word benefit
is meant to imply reduced risk of metastasis and death.
Table 1. Adjuvant and Salvage Radiotherapy After Prostatectomy: AUA/ASTRO Research Questions and Recommendations
Research question domains
1. Patient counseling
2. Use of radiotherapy in adjuvant and salvage contexts
3. Definition of biochemical recurrence
4. Conduct of restaging evaluation
Guideline recommendations
1. Patients who are being considered for management of localized prostate cancer with radical prostatectomy should be informed of potential for adverse
pathologic findings that portend higher risk of cancer recurrence and that these findings may suggest potential benefit of additional therapy after surgery
(clinical principle)
2. Patients with adverse pathologic findings, including seminal vesicle invasion, positive surgical margins, and extraprostatic extension, should be informed
that adjuvant radiotherapy, compared with radical prostatectomy only, reduces risk of biochemical (PSA) recurrence, local recurrence, and clinical
progression of cancer. They should also be informed that impact of adjuvant radiotherapy on subsequent metastases and overall survival is less clear; one
of two randomized controlled trials that addressed these outcomes indicated benefit, but the other trial did not demonstrate a benefit (clinical principle)
3. Physicians should offer adjuvant radiotherapy to patients with adverse pathologic findings at prostatectomy, including seminal vesicle invasion, positive
surgical margins, or extraprostatic extension, because of demonstrated reductions in biochemical recurrence, local recurrence, and clinical progression
(standard; evidence strength: grade A)
4. Patients should be informed that development of PSA recurrence after surgery is associated with higher risk of development of metastatic prostate
cancer or death resulting from disease; congruent with this clinical principle, physicians should regularly monitor PSA after radical prostatectomy to enable
early administration of salvage therapies if appropriate (clinical principle)
5. Clinicians should define biochemical recurrence as detectable or rising PSA value after surgery that is  0.2 ng/mL, with second confirmatory level  0.2
ng/mL (recommendation; evidence strength: grade C)
6. Restaging evaluation in patient with PSA recurrence may be considered (option; evidence strength: grade C)
7. Physicians should offer salvage radiotherapy to patients with PSA or local recurrence after radical prostatectomy, in whom there is no evidence of distant
metastatic disease (recommendation; evidence strength: grade C)
8. Patients should be informed that effectiveness of radiotherapy for PSA recurrence is greatest when administered at lower levels of PSA (clinical principle)
9. Patients should be informed of possible short- and long-term urinary, bowel, and sexual side effects of radiotherapy as well as of potential benefits of
controlling disease recurrence (clinical principle)
Abbreviations: ASTRO, American Society for Radiation Oncology; AUA, American Urological Association; PSA, prostate-specific antigen.
Data adapted.2
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Recommendation 3
In the first sentence, the word offer should be interpreted as
having a detailed discussion with the patient about the risks and
benefits of adjuvant radiotherapy. This discussion should be heavily
influenced by our additional qualifying statement and include a thor-
ough discussion of the absolute risk of recurrence in light of exact
pathologic findings and postoperative PSA levels. As such, although
adjuvant radiotherapy seems to be equally effective for all stages and
postoperative PSA levels in terms of reducing the relative risk of
recurrence, the absolute benefit is influenced by the absolute risk of
recurrence. For men at low risk of recurrence, the benefits are
modest. Moreover, all potential benefits must be weighed against
the known risks.
Recommendation 4
Although the endorsement panel concurs, as noted in the
discussion for guideline statement No. 3 and in our qualifying
statement, not all men are at equal risk of recurrence. At this time,
there are insufficient data to recommend different follow-up strat-
egies based on differing risk of recurrence, and thus, all men should
be observed after surgery.
Recommendation 5
Defining an exact cut point for PSA recurrence is challenging. We
acknowledge this difficulty, and although we agree that 0.2 ng/mL is a
reasonable cutoff and is widely used in research publications and in
clinical practice, the benefits of using this cut point versus others are
unclear. As such, we believe that the evidence to support this recom-
mendation was clinical practice rather than level C evidence.
Recommendation 6
Although the endorsement panel agrees with this statement,
the discussion centered on which imaging modalities to use. At this
time, there is no clear consensus, and unfortunately, all imaging
modalities have limited sensitivity and specificity in the low PSA
range, where salvage radiotherapy is most effective (ie, PSA  1
ng/mL). We note that this is a rapidly evolving field with much
research, and it is hoped that in the future, there will be more clarity
on this point.
Recommendation 7
The word offer should be interpreted as analogous to the discus-
sion regarding guideline statement No. 3.
Recommendation 8
Although PSA control rates are best when salvage radiotherapy is
administered when the PSA is  1 ng/mL, there is no guarantee of
cure, because salvage radiotherapy is not curative for all men. There
are many technical issues related to measuring the rate of PSA rise,
typically measured as PSA doubling time (PSADT; ie, when to start
counting, how many values, over what time period, and so on),5 but
data suggest a short PSADT predicts a poor response to salvage radio-
therapy in terms of PSA control.6 However, because these men are at
the highest risk of clinically meaningful progression,7 they stand the
most to gain from salvage radiotherapy, and indeed, retrospective data
suggest that salvage radiotherapy improves overall survival, albeit only
in those with a short PSADT.8
Finally, the ASCO endorsement panel added an additional qual-
ifying statement not paired with a specific recommendation as follows:
Not all men who are candidates for adjuvant radiotherapy have
the same risk of recurrence, and although radiotherapy is equally
effective in terms of relative risk reduction, not all men will derive the
same benefit. Items such as Gleason score (especially Gleason score 8
to 10), pathologic findings (especially seminal vesicle invasion or ex-
tensive positive margins), and an elevated postoperative PSA place
men at particularly high risk of recurrence or clinical progression, and
these men likely derive the greatest benefit in terms of absolute risk
reduction from adjuvant radiotherapy. For other men, the absolute
risk benefit is likely lower, resulting in a less favorable risk-benefit
ratio. Similarly, not all men who develop a PSA recurrence have the
same risk of clinically meaningful disease progression, and therefore,
the risk-benefit ratio for salvage radiotherapy is likewise different for
each patient.
The panel thought it was critical to highlight this point. As with
the initial decision to undergo radical prostatectomy, deciding on
adjuvant or salvage radiotherapy involves a consideration of the risk-
benefit ratio. Although the risks are known, the benefits will vary for
each patient based on his own risk of recurrence. Fortunately, this risk
can be calculated using nomograms that incorporate not only preop-
erative and pathologic findings but also postoperative PSA values.9
Specifically, some men who are candidates for adjuvant radiotherapy
based on entry criteria in reported clinical trials and an undetectable
PSA may have favorable outcomes (ie, those with focal positive mar-
gins or low prostatectomy Gleason score), and for these men, the
absolute benefits of adjuvant radiotherapy (compared with early
salvage radiotherapy) may be low. Alternatively, men with more
favorable pathology but a detectable postoperative PSA can be at
high risk of clinically meaningful recurrence and thus stand to
experience great benefits with adjuvant radiotherapy. Likewise,
many men with a PSA recurrence, which can occur years after
surgery when the patient has developed more comorbidities, have
an indolent disease course.7 In these men, the benefits of salvage
radiotherapy are likely low. Alternatively, others can experience an
aggressive recurrence with a short PSADT, for which retrospective
data suggest a survival advantage for salvage radiotherapy.8 Thus,
there needs to be a risk-stratified approach to the discussion re-
garding the risk-benefit ratio of adjuvant and salvage radiotherapy.
ENDORSEMENT RECOMMENDATION
ASCO endorses the AUA/ASTRO guideline on adjuvant and salvage
radiotherapy after prostatectomy by Thompson et al,2 published in
2013 in Journal of Urology, with qualifying statements developed by
the Endorsement Panel.
ADDITIONAL RESOURCES
More information, including a Data Supplement, a Methodology
Supplement, slide sets, and clinical tools and resources, is available at
www.asco.org/endorsements/adjuvantRTprostatectomy. Patient in-
formation is available at www.cancer.net.
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